Birchview Capital’s Stoke Therapeutics STOK Stock Holding History

Birchview Capital’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.84M	Sell	210,000 -50,000	-19%	-$1.64M	3.89%	5
2025 Q4	$8.25M	Buy	260,000 +50,000	+24%	+$1.5M	4.83%	4
2025 Q3	$4.93M	Hold	210,000	–	–	3.73%	5
2025 Q2	$2.38M	Sell	210,000 -5	-0%	-$47	2.37%	10
2025 Q1	$1.4M	Buy	210,005 +5	+0%	+$47	1.21%	21
2024 Q4	$2.32M	Hold	210,000	–	–	1.88%	16
2024 Q3	$2.58M	Hold	210,000	–	–	2.23%	14
2024 Q2	$2.84M	Hold	210,000	–	–	2.62%	11
2024 Q1	$2.83M	Hold	210,000	–	–	2.31%	10
2023 Q4	$1.1M	Buy	210,000 +125,000	+147%	+$534K	0.86%	24
2023 Q3	$335K	Hold	85,000	–	–	0.28%	39
2023 Q2	$904K	Buy	85,000 +70,000	+467%	+$745K	0.68%	26
2023 Q1	$125K	Hold	15,000	–	–	0.1%	50
2022 Q4	$138K	Hold	15,000	–	–	0.1%	51
2022 Q3	$193K	Hold	15,000	–	–	0.14%	51
2022 Q2	$198K	Hold	15,000	–	–	0.14%	51
2022 Q1	$316K	Hold	15,000	–	–	0.23%	50
2021 Q4	$360K	Hold	15,000	–	–	0.23%	51
2021 Q3	$382K	Hold	15,000	–	–	0.26%	48
2021 Q2	$505K	Hold	15,000	–	–	0.3%	44
2021 Q1	$583K	Sell	15,000 -5,000	-25%	-$285K	0.35%	41
2020 Q4	$1.24M	Hold	20,000	–	–	0.71%	24
2020 Q3	$670K	Hold	20,000	–	–	0.45%	28
2020 Q2	$477K	Hold	20,000	–	–	0.29%	37
2020 Q1	$458K	Buy	+20,000	New	+$494K	0.41%	30

Other funds holding STOK

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Birchview Capital's STOK Position: Q1 2026 in Review

Birchview Capital reduced its Stoke Therapeutics (STOK) stake by 19% in Q1 2026, selling an estimated $1.64M and leaving 210,000 shares worth $6.84M. The position accounts for 3.89% of the portfolio, ranked #5.

Birchview Capital first reported a position in STOK in Q1 2020 and has held it in 25 quarters since. The position peaked at $8.25M in Q4 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

Birchview Capital held 210,000 shares of Stoke Therapeutics worth $6.84M as of Q1 2026.
Birchview Capital sold 50,000 Stoke Therapeutics shares in Q1 2026, an estimated $1.64M.
Stoke Therapeutics made up 3.89% of Birchview Capital's portfolio in Q1 2026, its #5 holding.
Birchview Capital first reported a position in Stoke Therapeutics in Q1 2020 and has held it in 25 quarters since.
Birchview Capital's Stoke Therapeutics position peaked at $8.25M in Q4 2025.
196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.